Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 fiscal 2026 results for quarter ended March 31, 2026.
Oric Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 fiscal 2026 results for quarter ended March 31, 2026
- Press release issued May 4, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Rinzimetostat 400 mg selected for Phase 3 Himalayas-1 in post-abiraterone mCRPC, with trial initiation expected in 1H 2026
- Rinzimetostat showed 5-month rPFS of 84%, PSA50 response in 47% of patients, and >50% ctDNA reduction in 71%
- Safety profile remained favorable, with one Grade 3 treatment-related adverse event and no Grade 4 or 5 events attributed to treatment
- Cash and investments of $419.7 million, including $59.9 million from ATM proceeds, expected to fund operations into 2H 2028
- Net loss increased to $35.8 million from $30.0 million as R&D expenses rose to $31.4 million from $24.6 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oric Pharmaceuticals, Inc. 8-K filings
Get the next ORIC 8-K as it lands
Follow ORIC for push alerts, or ask the research agent what this filing means.